Select a month January 2004 December 2003 November 2003" October 2003 September 2003 July 2003 June 2003 May 2003 April 2003 March 2003 February 2003 January 2003 December 2002 November 2002 October 2002 September 2002 August 2002 July 2002 June 2002 May 2002 April 2002 March 2002 February 2002 January 2002 December 2001 November 2001 October 2001

Non-Human/In-Vitro Studies: Neurotoxicity (Definition) Jump to: 2003: January  |  February  |  March  |  April  |   May  |   June  |   July  |   2002: January  |  February  |  March  |  April  |  May  |  June  |  July  |  August  |  September  |  October  |  November  |  December   2001: October  |  November  |  December July 2003 No updates available at this time. June 2003 Bogen IL, Haug KH, Myhre O, Fonnum F (2003) Short- and long-term effects of MDMA ("ecstasy") on synaptosomal and vesicular uptake of neurotransmitters in vitro and ex vivo. Neurochem Int 43: 393-400. Bowyer JD, Young JF, Slikker W, Itzhak Y, Mayorga AJ, Newport GD, Ali SF, Frederick DL, Paule MG (2003) Plasma levels of parent compound and metabolites after doses of either fenfluramine or d-3,4-methylenedioxymethamphetamine (MDMA) that produce long-term serotonergic alterations. NeuroToxicology 24; 379-390 Schmued LC (2003) Demonstration and localization of neuronal degeneration in the rat forebrain following a single exposure to MDMA. Brain Res 974: 127-133. May 2003 McGregor IS, Gurtman CG, Morley KC, Clemens KJ, Blokland A, Li KM, Cornish JL, Hunt GE (2003) Increased anxiety and "depressive" symptoms months after MDMA ("ecstasy") in rats: drug-induced hyperthermia does not predict long-term outcomes. Psychopharmacology 17:17 McGregor IS, Clemens KJ, Van Der Plasse G, Li KM, Hunt GE, Chen F, Lawrence AJ (2003) Increased Anxiety 3 Months after Brief Exposure to MDMA ('Ecstasy') in Rats: Association with Altered 5-HT Transporter and Receptor Density. Neuropsychopharmacology 16:16 April 2003 Bull EJ, Hutson PH, Fone KC (2003) Reduced social interaction following 3,4-methylenedioxymethamphetamine is not associated with enhanced 5-HT(2C) receptor responsivity. Neuropharmacology 44: 439-448. Pubill D, Canudas AM, Pallas M, Camins A, Camarasa J, Escubedo E (2003) Different glial response to methamphetamine- and methylenedioxymethamphetamine-induced neurotoxicity. Naunyn Schmiedebergs Arch Pharmacol 9: 9 Published On-Line. Sanchez V, Camarero J, O'Shea E, Green AR, Colado MI (2003) Differential effect of dietary selenium on the long-term neurotoxicity induced by MDMA in mice and rats. Neuropharmacology 44: 449-61. Williams MT, Morford LL, Wood SL, Rock SL, McCrea AE, Fukumura M, Wallace TL, Broening HW, Moran MS, Vorhees CV (2003) Developmental 3,4-methylenedioxymethamphetamine (MDMA) impairs sequential and spatial but not cued learning independent of growth, litter effects or injection stress. Brain Res 968: 89-101. March 2003 Cole JC, Sumnall HR, O'Shea E, Marsden CA (2003) Effects of MDMA exposure on the conditioned place preference produced by other drugs of abuse. Psychopharmacology 25:25 Itzhak Y, Ali SF, Achat CN, Anderson KL (2003) Relevance of MDMA ("ecstasy")-induced neurotoxicity to long-lasting psychomotor stimulation in mice. Psychopharmacology 166: 241-248. February 2003 Ferrucci M, Gesi M, Lenzi P, Soldani P, Ruffoli R, Pellegrini A, Ruggieri S, Paparelli A, Fornai F (2002) Noradrenergic loss enhances MDMA toxicity and induces ubiquitin-positive striatal whorls. Neurol Sci 23 Suppl 2: S75-S76 January 2003 No updates available for January 2003 December 2002 Colbron S, Jones M, Biello SM (2002) MDMA alters the response of the circadian clock to a photic and non-photic stimulus. Brain Res 956: 45-52. Kelly PA, Ritchie IM, Quate L, McBean DE, Olverman HJ (2002) Functional consequences of perinatal exposure to 3,4-methylenedioxymethamphetamine in rat brain. Br J Pharmacol 137: 963-970. Taffe MA, Davis SA, Yuan J, Schroeder R, Hatzidimitriou G, Parsons LH, Ricaurte GA, Gold LH (2002) Cognitive Performance of MDMA-Treated Rhesus Monkeys. Sensitivity to Serotonergic Challenge. Neuropsychopharmacology 27: 993-1005. November 2002 Boot BP, Mechan AO, McCann UD, Ricaurte GA (2002). MDMA- and p-chlorophenylalanine-induced reduction in 5-HT concentrations: effects on serotonin transporter densities. Eur J Pharmacol 453: 239-244 Gobbi M, Moia M, Pirona L, Ceglia I, Reyes-Parada M, Scorza C, Mennini T (2002). p-Methylthioamphetamine and 1-(m-chlorophenyl)piperazine, two non-neurotoxic 5-HT releasers in vivo, differ from neurotoxic amphetamine derivatives in their mode of action at 5-HT nerve endings in vitro. J Neurochem 82: 1435-1443. Jiang XR, Dryhurst G (2002) Inhibition of the alpha-ketoglutarate dehydrogenase and pyruvate dehydrogenase complexes by a putative aberrant metabolite of serotonin, tryptamine-4,5-dione. Chem Res Toxicol 15: 1242-1247 Kanthasamy A, Sprague J, Shotwell J, Nichols D (2002)Unilateral infusion of a dopamine transporter antisense into the substantia nigra protects against MDMA-induced serotonergic deficits in the ipsilateral striatum. Neuroscience 114: 917-924 Yuan J, Cord BJ, McCann UD, Callahan BT, Ricaurte GA (2002) Effect of glucoprivation on serotonin neurotoxicity induced by substituted amphetamines. J Pharmacol Exp Ther 303: 831-839 October 2002 Fernandez F, Aguerre S, Mormede P, Chaouloff F (2002) Influences of the corticotropic axis and sympathetic activity on neurochemical consequences of 3,4-methylenedioxymethamphetamine (MDMA) administration in Fischer 344 rats. Eur J Neurosci 16: 607-618. Green AR, McGregor IS (2002) On the anxiogenic and anxiolytic nature of long-term cerebral 5-HT depletion following MDMA. Psychopharmacology (Berl) 162: 448-450. Holden C (2002) Neuroscience: Drug find could give ravers the jitters. Science, 297: 2185, 2187. Reneman L, Booij J, Habraken JB, De Bruin K, Hatzidimitriou G, Den Heeten GJ, Ricaurte GA (2002) Validity of [123I]beta-CIT SPECT in detecting MDMA-induced serotonergic neurotoxicity. Synapse 46: 199-205. Ricaurte GA, Yuan J, Hatzidimitriou G, Cord BJ, McCann UD (2002) Severe Dopaminergic Neurotoxicity in Primates After a Common Recreational Dose Regimen of MDMA ("Ecstasy"). Science 297: 2260-2263. September 2002 No updates available for September 2002 August 2002 Ellison G (2002) Neural degeneration following chronic stimulant abuse reveals a weak link in brain, fasciculus retroflexus, implying the loss of forebrain control circuitry. Eur Neuropsychopharmacol 12: 287-97. Fornai F, Gesi M, Lenzi P, Ferrucci M, Pellegrini A, Ruggieri S, Casini A, Paparelli A (2002) Striatal postsynaptic ultrastructural alterations following methylenedioxymethamphetamine administration. Ann N Y Acad Sci 965: 381-98. Meyer JS, Ali SF (2002) Serotonergic neurotoxicity of MDMA (ecstasy) in the developing rat brain. Ann N Y Acad Sci 965: 373-80. Morley-Fletcher S, Bianchi M, Gerra G, Laviola G (2002) Acute and carryover effects in mice of MDMA ("ecstasy") administration during periadolescence. Eur J Pharmacol 448: 31-8. Won L, Bubula N, Heller A (2002) Fetal exposure to (+/-)-methylenedioxymethamphetamine in utero enhances the development and metabolism of serotonergic neurons in three-dimensional reaggregate tissue culture. Brain Res Dev Brain Res 137: 67-73. July 2002 Camarero J, Sanchez V, O'Shea E, Green AR, Colado MI (2002) Studies, using in vivo microdialysis, on the effect of the dopamine uptake inhibitor GBR 12909 on 3,4-methylenedioxymethamphetamine ('ecstasy')-induced dopamine release and free radical formation in the mouse striatum. J Neurochem 81: 961-72. Gurtman CG, Morley KC, Li KM, Hunt GE, McGregor IS (2002) Increased anxiety in rats after 3,4-methylenedioxymethamphetamine: association with serotonin depletion. Eur J Pharmacol 446: 89-96. O'Shea E, Easton N, Fry JR, Green AR, Marsden CA (2002) Protection against 3,4-methylenedioxymethamphetamine-induced neurodegeneration produced by glutathione depletion in rats is mediated by attenuation of hyperthermia. J Neurochem 81: 686-695. June 2002 Falk, EM, Cook VJ, Nichols DE, Sprague JE (2002). An antisense oligonucleotide targeted at MAO-B attenuates rat striatal serotonergic neurotoxicity induced by MDMA. Pharmacol Biochem Behav 72: 617-622. May 2002 Szabo Z, McCann UD, Wilson AA, Scheffel U, Owonikoko T, Mathews WB, Ravert HT, Hilton J, Dannals RF, Ricaurte GA (2002). Comparison of (+)-(11)C-McN5652 and (11)C-DASB as Serotonin Transporter Radioligands Under Various Experimental Conditions. J Nucl Med, 43(5): 678-692 April 2002 Darvesh, AS, Shankaran M, Gudelsky GA (2002). 3,4-methylenedioxymethamphetamine produces glycogenolysis and increases the extracellular concentration of glucose in the rat brain. J Pharmacol Exp Ther 301: 138-144 Johnson EA, O'Callaghan JP, Miller DB (2002). Chronic treatment with supraphysiological levels of corticosterone enhances D-MDMA-induced dopaminergic neurotoxicity in the C57BL/6J female mouse. Brain Res 933: 130-138 Johnson EA, Shvedova AA, Kisin E, O'Callaghan JP, Kommineni C, Miller DB (2002). d-MDMA during vitamin E deficiency: effects on dopaminergic neurotoxicity and hepatotoxicity. Brain Res 933: 150-163 Yuan J, Cord BJ, McCann UD, Callahan BT, Ricaurte GA (2002). Effect of depleting vesicular and cytoplasmic dopamine on methylenedioxymethamphetamine neurotoxicity. J Neurochem, 80: 960-969 March 2002 Hatzidimitriou G, Tsai EH, McCann UD, Ricaurte GA (2002). Altered prolactin response to M-chlorophenylpiperazine in monkeys previously treated with 3,4-methylenedioxymethamphetamine (MDMA) or fenfluramine. Synapse 44: 51-57. Matuszewich L, Filon ME, Finn DA, Yamamoto BK (2002). Altered forebrain neurotransmitter responses to immobilization stress following 3,4-methylenedioxymethamphetamine. Neuroscience 110: 41-8 Reneman L, Endert E, de Bruin K, Lavalaye J, Feenstra MG, de Wolff F, Booij J (2002). The acute and chronic effects of MDMA ("Ecstasy") on cortical 5HT2A receptors in rat and human brain. Neuropsychopharmacology, 26: 387-396 February 2002 Winsauer PJ, McCann, UD, Delatte MS, Stevenson, MW, Ricaurte GA, Moerschbaecher JM (2002). Effects of fenfluramine, m-CPP and triazolam on repeated acquisition in squirrel monkeys before and after neurotoxic MDMA administration. Psychopharmacology (Berl) 159: 388-396 January 2002 Callahan BT, Cord BJ, Ricaurte GA (2001). Long-term impairment of anterograde axonal transport along fiber projections originating in the rostral raphe nuclei after treatment with fenfluramine or methylenedioxymethamphetamine. Synapse 40: 113-21. Fornai F, Giorgi FS, Gesi M, Chen K, Alessri MG, Shih JC (2001). Biochemical effects of the monoamine neurotoxins DSP-4 and MDMA in specific brain regions of MAO-B-deficient mice. Synapse 39: 213-21. Mechan AO, Moran PM, Elliott JM, Young AMJ, Joseph M, Green AR (2002). A study of the effects of a single neurotoxic dose of 3,4-methyelenedioxymethamphetamine (MDMA, "ecstasy") on the subsequent long-term behavior of rats in the plus maze and open field. Psychopharmacology (Berl), 159; 167-175. December 2001 Colado MI, Camarero J, Mechan AO, Sanchez V, Esteban B, Elliott JM, Green AR (2001). A study of the mechanisms involved in the neurotoxic action of 3,4- methylenedioxymethamphetamine (MDMA, 'ecstasy') on dopamine neurones in mouse brain. Br J Pharmacol 134: 1711-23. November 2001 No updates available for November 2001 October 2001 O'Loinsigh, ED, Boland, G, Kelly, JP and O'Boyle, KM (2001). Behavioral, hyperthermic and neurotoxic effects of 3,4-methylenedioxymethamphetamine analogues in the Wistar rat. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 25: 621-638 Sanchez, V, Camarero, J, Esteban, B, Peter, MJ, Green, AR and Colado, MI (2001). The mechanisms involved in the long-lasting neuroprotective effect of fluoxetine against MDMA ("ecstasy")-induced degeneration of 5-HT nerve endings in rat brain. British Journal of Pharmacology, 134: 46-57